The Firm recently represented Deutsche Bank Securities Inc. and J.P. Morgan Securities LLC, as initial purchasers, in connection with a US$300 million international offering of 5.125% Senior Notes due 2022 by CFR Pharmaceuticals S.A. and certain of its subsidiaries. The offering was made to qualified institutional buyers in reliance on Rule 144A and outside the United States to non-U.S. persons in reliance on Regulation S under the Securities Act. The net proceeds from the offering is expected to finance part of the purchase price for CFR’s acquisition of Laboratorio Franco Colombiano Lafrancol S.A.S.
Headquartered in Chile, CFR is a leading Latin American pharmaceutical company with operations in 15 countries across the region and certain other emerging markets. CFR focuses on the development, manufacture and commercialization of off-patent and locally unpatented, branded, specialty pharmaceutical products. Lafrancol develops, manufactures and commercializes pharmaceutical products principally in Colombia.
The Simpson Thacher team for this transaction included Juan Francisco Mendez, Juan M. Naveira, Regina Madrid and Lauren Yoon (Capital Markets); Alan Brenner, Brian Korchin and Alex Coedo (Credit); and Jonathan Cantor, Chang Won Choi and Jodi Sackel (Tax).
